Seres Health is a microbiome therapeutics platform company developing Ecobiotic® biological drugs designed to treat diseases by restoring a dysbiotic microbiome. Its lead product candidate, SER-109, is being developed to prevent recurrence of Clostridium difficile infection. The company intends to advance SER-109 into Phase 3 clinical trials using the new funding. Seres also plans to progress a pipeline of therapeutics targeting other diseases of the human microbiome. Current product candidates span infectious, metabolic, and inflammatory diseases. The company is led by Dr. Roger J. Pomerantz, President, CEO and Chairman. Seres Health is a clinical-stage microbiome therapeutics platform developing Ecobiotic® biological drugs designed to restore the function of dysbiotic microbiomes. Its lead product candidate is SER-109, aimed at preventing recurrence of Clostridium difficile infection, and its pipeline spans infectious, metabolic, and inflammatory diseases. The company plans to advance SER-109 into Phase 3 clinical trials using proceeds from its recent financing. Seres closed a $48M Series C and has received over $65M in funding to date. Founded in 2012 with initial funding from Flagship Ventures and led by Dr. Roger J. Pomerantz, the company is based in Cambridge, Mass. It recently announced a research alliance with Mayo Clinic to support its development programs. Seres Health is a clinical-stage therapeutics company developing Ecobiotic® products that target the human microbiome to treat infectious, metabolic, and inflammatory diseases. Its lead candidate, SER-109, is in clinical testing for the treatment of recurrent C. difficile. The company intends to use the Series B proceeds to advance its pipeline of therapeutics. Seres has entered into an exclusive research collaboration with the Mayo Clinic to define diseases amenable to microbiome-based interventions and to aid discovery and development. Launched in 2012 by Dr. Roger J. Pomerantz and founded by Flagship VentureLabs, the company is advancing multiple candidates across disease areas. Seres Health is a clinical-stage therapeutics company focused on developing products derived from human microbiome science. Led by CEO and co‑founder Dr. David Berry, the company emerged from two years in stealth and launched publicly with Series A funding. Its research originates from work by Flagship VentureLabs, which began developing the underlying technology platforms in 2010 after a three‑year exploration into microbiome biology. Seres is developing candidates to treat infectious, metabolic, and inflammatory diseases. Its lead candidate, SER-109, is undergoing clinical testing to treat C. difficile infection, a major cause of antibiotic-associated diarrhea. The company’s current financing position was established with a $10.5M Series A.

Total raised

$134M

Funding rounds

4

Latest round

Series D

Latest activity

Jan 2015